Cellestia Biotech’s Post

This week, four Swiss #biotech startups joined us in Boston for a three-day program on their way to the BIO International Convention in San Diego next week. Meet the startups and find out more about their experience in Boston as part of the Innosuisse Internationalization Camps! 🚀 The startups are: Nagi Bioscience, whose SydLab System is a benchtop laboratory device allowing standardized drug and chemical testing on microorganisms within disposable microfluidic cartridges. mimiX Biotherapeutics which has developed FastSkin, a dermal substitute developed by mimiX using their Sound Induced Morphogenesis technology, offers a novel solution to help patients struggling to heal from complex wounds. Cellestia Biotech is a fully integrated R&D company specialized in innovative therapeutics with new modes of action to treat autoimmune diseases and multidrug resistant cancers. Amphilix AG is developing small molecular chimeras utilizing a unique linker platform that enables fine-tuning of molecular properties, raising the bar for standard-of-care treatment and addressing unmet medical needs. Here’s what they’ve been up to this week: ⚖️ In a session on incorporation with Laura Stoffel (Gunderson Dettmer) they discussed types of legal structures in the US and their implications. 👨💻 With Alexander Harrall (TriNet) they learned how to hire in the US and discover cultural differences in the recruitment process to attract the best talent. 📃 James Ravitz (McDermott Will & Emery) shared insights on the FDA’s regulatory approval process and got them ready for expansion. 🧪 With Alberto Nobili, the startups got the chance to tour Bayer Co.Lab, an incubator for early-stage healthcare startups. 👥 In a feedback session with investors Doug Zingale and Edward Melia the startups got invaluable advice on their pitches and practiced how to adjust them to the local audience. 🗃️ In a session on taxation with Gerhard Friedrich Schneiders (Rödl & Partner USA) they discussed differences between Switzerland and the US, and the tax implications of different legal entities. 📣 Finally, with Mehdi Aghdaee, MD, PhD (#QuantLifeSciences), they worked on their storytelling skills, practicing how to create a storyline and capture an audience - which will come in handy next week! We welcomed the startups to the US with our Biotech Garden Party, where they were able to meet and network with members of Boston’s biotech community, including representatives from Novartis, Sanofi, Pfizer, and many others who will be attending #BIO2024. Thanks to all who attended the event, and especially to Innosuisse, Greater Zurich Area, Greater Geneva Bern area (GGBa), and Switzerland Global Enterprise for their partnership. Thank you as well to all the experts who shared their time and knowledge with the startups throughout the week! 🙏🏼 Next stop, San Diego! 🌴 #SwissBiotech #SwissStartups